CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway

BACKGROUND: Cisplatin (DDP) is standard-of-care and first-line management for ovarian cancer (OvCa). Circular RNA HIPK2 (circHIPK2) is abnormally upregulated in serum of OvCa patients. However, its role in DDP resistance remains unclear. METHODS: Expression of cirHIPK2, microRNA (miR)-338-3p and chr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yang, Xie, Xin, Li, Mingzhu, Gao, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128508/
https://www.ncbi.nlm.nih.gov/pubmed/34012271
http://dx.doi.org/10.2147/OTT.S291823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128508/
https://www.ncbi.nlm.nih.gov/pubmed/34012271
http://dx.doi.org/10.2147/OTT.S291823

Ejemplares similares